(688767)"HANGZHOU BIOTEST BIOTECH CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688767 · · 16 pages · Chinese
Summary by 6ix AI
The report indicates a decline in total revenue and net profit compared to the previous year, with significant losses reported. The company assures that the report's content is accurate and complete, with no false statements or omissions. The financial statements included in the report have not been audited.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Hangzhou Biotest Biotech Co., Ltd. on 6ix
Earlier from Hangzhou Biotest Biotech
- Announcement on Resolutions of the 9th Meeting of the 4th Board of Directors
- Review Opinion and Statement on the Public Disclosure of the List of Participants under the Company's 2026 Restricted Share Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors
- Announcement on Summary of 2026 Restricted Share Incentive Plan (Draft)
- Announcement on Implementation Results of Share Repurchase
- Announcement on Progress in Repurchasing 1% Shares through Call Auction
Follow Hangzhou Biotest Biotech into a list and get an email when it puts out news.
Follow Hangzhou Biotest Biotech